4
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Use of Immunomodulating Drugs and Risk of Cutaneous Melanoma: A Nationwide Nested Case-Control Study

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Purpose

          Cutaneous melanoma is among the fastest growing malignancies in Norway and ultraviolet radiation (UVR) exposure is the primary environmental risk factor. Immunomodulating drugs can increase skin photosensitivity and suppress immune responses, and by such mechanisms influence melanoma risk. We, therefore, aimed to examine the associations between use of immunomodulating drugs and melanoma risk, at a nationwide population level.

          Patients and Methods

          In the Cancer Registry of Norway, we identified all cases aged 18–85 with a first primary cutaneous melanoma diagnosed in 2007–2015 (n=12,106). These were matched to population controls from the Norwegian National Registry 1:10 (n=118,564), on sex and year of birth using risk set sampling. Information on prescribed drugs (2004–2015) was obtained by linkage to the Norwegian Prescription Database (NorPD). Conditional logistic regression was used to estimate rate ratios (RRs) and 95% confidence intervals (CIs) for associations between use of immunomodulating drugs (immunosuppressants and corticosteroids) and melanoma risk, adjusted for ambient UVR and other drug use.

          Results

          Compared with ≤1 prescription, use of ≥8 prescriptions of immunosuppressants was associated with increased risk of melanoma (RR 1.50, 95% CI 1.27, 1.77). Similar associations were found for subgroups of immunosuppressants: drugs typically prescribed to organ transplant recipients (OTRs) (RR 2.02, 95% CI 1.35, 3.03) and methotrexate (RR 1.27, 95% CI 1.04, 1.55). Similar results were found for high levels of cumulative doses and across all histological subtypes. Use of corticosteroids was not associated with melanoma risk.

          Conclusion

          We found a positive association between use of immunosuppressants and melanoma risk, with the highest risk seen for drugs prescribed to OTRs. Knowledge about this risk increase is important for physicians and users of these drugs, for intensified surveillance, awareness and cautious sun exposure.

          Related collections

          Most cited references69

          • Record: found
          • Abstract: found
          • Article: not found

          The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights

          Since the discovery of glucocorticoids in the 1940s and the recognition of their anti-inflammatory effects, they have been amongst the most widely used and effective treatments to control inflammatory and autoimmune diseases. However, their clinical efficacy is compromised by the metabolic effects of long-term treatment, which include osteoporosis, hypertension, dyslipidaemia and insulin resistance/type 2 diabetes mellitus. In recent years, a great deal of effort has been invested in identifying compounds that separate the beneficial anti-inflammatory effects from the adverse metabolic effects of glucocorticoids, with limited effect. It is clear that for these efforts to be effective, a greater understanding is required of the mechanisms by which glucocorticoids exert their anti-inflammatory and immunosuppressive actions. Recent research is shedding new light on some of these mechanisms and has produced some surprising new findings. Some of these recent developments are reviewed here.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Data quality at the Cancer Registry of Norway: an overview of comparability, completeness, validity and timeliness.

            To provide a comprehensive evaluation of the quality of the data collected on both solid and non-solid tumours at the Cancer Registry of Norway (CRN). Established quantitative and semi-quantitative methods were used to assess comparability, completeness, accuracy and timeliness of data for the period 1953-2005, with special attention to the registration period 2001-2005. The CRN coding and classification system by and large follows international standards, with some further subdivisions of morphology groupings performed in-house. The overall completeness was estimated at 98.8% for the registration period 2001-2005. There remains a variable degree of under-reporting particularly for haematological malignancies (C90-95) and tumours of the central nervous system (C70-72). For the same period, 93.8% of the cases were morphologically verified (site-specific range: 60.0-99.8%). The under-reporting in 2005 due to timely publication is estimated at 2.2% overall, based on the number of cases received at the registry during the following year. This review suggests the routines in place at the CRN yields comparable data that can be considered reasonably accurate, close-to-complete and timely, thereby justifying our policy of the reporting of annual incidence one year after the year of diagnosis.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              The global burden of melanoma: results from the Global Burden of Disease Study 2015

              Summary Background Despite recent improvements in prevention, diagnosis and treatment, vast differences in melanoma burden still exist between populations. Comparative data can highlight these differences and lead to focused efforts to reduce the burden of melanoma. Objectives To assess global, regional and national melanoma incidence, mortality and disability‐adjusted life year (DALY) estimates from the Global Burden of Disease Study 2015. Methods Vital registration system and cancer registry data were used for melanoma mortality modelling. Incidence and prevalence were estimated using separately modelled mortality‐to‐incidence ratios. Total prevalence was divided into four disease phases and multiplied by disability weights to generate years lived with disability (YLDs). Deaths in each age group were multiplied by the reference life expectancy to generate years of life lost (YLLs). YLDs and YLLs were added to estimate DALYs. Results The five world regions with the greatest melanoma incidence, DALY and mortality rates were Australasia, North America, Eastern Europe, Western Europe and Central Europe. With the exception of regions in sub‐Saharan Africa, DALY and mortality rates were greater in men than in women. DALY rate by age was highest in those aged 75–79 years, 70–74 years and ≥ 80 years. Conclusions The greatest burden from melanoma falls on Australasian, North American, European, elderly and male populations, which is consistent with previous investigations. These substantial disparities in melanoma burden worldwide highlight the need for aggressive prevention efforts. The Global Burden of Disease Study results can help shape melanoma research and public policy.
                Bookmark

                Author and article information

                Journal
                Clin Epidemiol
                Clin Epidemiol
                clep
                clinepid
                Clinical Epidemiology
                Dove
                1179-1349
                18 December 2020
                2020
                : 12
                : 1389-1401
                Affiliations
                [1 ]Department of Research, Cancer Registry of Norway , Oslo, Norway
                [2 ]Oslo Centre for Biostatistics and Epidemiology, Department of Biostatistics, Institute of Basic Medical Sciences, University of Oslo , Oslo, Norway
                [3 ]Institute for Cancer Research, Oslo University Hospital , Oslo, Norway
                [4 ]Division of Emergencies and Critical Care, Oslo University Hospital , Oslo, Norway
                [5 ]Institute of Clinical Medicine, Faculty of Medicine, University of Oslo , Oslo, Norway
                [6 ]Oslo Ischemia Study, Oslo University Hospital , Oslo, Norway
                [7 ]Department of Chronic Diseases and Ageing, Norwegian Institute of Public Health , Oslo, Norway
                [8 ]Department of Radiation Biology, Institute for Cancer Research, Oslo University Hospital , Oslo, Norway
                [9 ]Oslo Centre for Biostatistics and Epidemiology, Oslo University Hospital , Oslo, Norway
                [10 ]Department of Registration, Cancer Registry of Norway , Oslo, Norway
                [11 ]Population Health Department, QIMR Berghofer Medical Research Institute , Brisbane, Australia
                [12 ]Molecular Oncology Unit, CRUK Manchester Institute, University of Manchester , Manchester, UK
                Author notes
                Correspondence: Leon Alexander Mclaren Berge Cancer Registry of Norway , Majorstuen, OsloN-0304, NorwayTel +47 99605034 Email Leon.Berge@kreftregisteret.no
                Author information
                http://orcid.org/0000-0002-1645-5582
                http://orcid.org/0000-0002-1964-5410
                http://orcid.org/0000-0001-9616-0145
                http://orcid.org/0000-0003-1204-787X
                http://orcid.org/0000-0001-9426-0062
                http://orcid.org/0000-0002-9601-5324
                http://orcid.org/0000-0002-2753-4841
                http://orcid.org/0000-0002-2083-2758
                http://orcid.org/0000-0002-1652-7734
                Article
                269446
                10.2147/CLEP.S269446
                7755337
                33376408
                26a365c3-a933-43f4-afc3-9329bbc2de44
                © 2020 Berge et al.

                This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.php).

                History
                : 29 July 2020
                : 08 October 2020
                Page count
                Figures: 0, Tables: 10, References: 70, Pages: 13
                Funding
                Funded by: the South-Eastern Norway Regional Health Authority;
                The study is funded by the South-Eastern Norway Regional Health Authority (no. 16/00451-33).
                Categories
                Original Research

                Public health
                immunosuppressants,corticosteroids,melanoma,prescription drugs,pharmacoepidemiology,registry-based

                Comments

                Comment on this article